India, Oct. 11 -- Roche (RHHBY,RO.SW,ROG.SW) announced positive one-year results from its Phase III MEERKAT and SANDCAT studies evaluating investigational therapy vamikibart in adults with uveitic macular edema (UME), reinforcing the treatment's potential to improve vision and reduce retinal swelling over the long term.
The studies compared vamikibart with a sham procedure designed to mimic intravitreal eye injections. At 52 weeks, patients treated with vamikibart demonstrated sustained gains in vision and continued reductions in central subfield thickness, a key measure of swelling in the retina caused by fluid accumulation.
Across both trials, a greater proportion of patients receiving vamikibart achieved clinically meaningful vision im...